Kura Oncology Inc
NASDAQ:KURA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Kura Oncology Inc
NASDAQ:KURA
|
US |
|
L
|
Leong Hup International Bhd
KLSE:LIIHEN
|
MY |
|
Wira Global Solusi Tbk PT
IDX:WGSH
|
ID |
|
Eutelsat Communications SA
PAR:ETL
|
FR |
|
Dareway Software Co Ltd
SSE:688579
|
CN |
|
T
|
Tangshan Sunfar Silicon Industries Co Ltd
SSE:603938
|
CN |
Kura Oncology Inc
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. The company is headquartered in San Diego, California and currently employs 121 full-time employees. The company went IPO on 2015-11-05. The Company’s segment is engaged in discovery and development of medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. The company is developing its product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and hematologic indications. The company is developing KO-539, a small molecule inhibitor of the Lysine K-specific Methyltransferase 2A (KMT2A) interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The firm is developing orally available, small molecule compounds that inhibit the interaction between the proteins menin and MLL for the treatment of MLL-rearranged (MML-r) leukemias, a genetically-defined subset of approximately two forms of acute leukemia, acute myeloid leukemia (AML) and acute lymphoblastic.
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. The company is headquartered in San Diego, California and currently employs 121 full-time employees. The company went IPO on 2015-11-05. The Company’s segment is engaged in discovery and development of medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. The company is developing its product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and hematologic indications. The company is developing KO-539, a small molecule inhibitor of the Lysine K-specific Methyltransferase 2A (KMT2A) interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The firm is developing orally available, small molecule compounds that inhibit the interaction between the proteins menin and MLL for the treatment of MLL-rearranged (MML-r) leukemias, a genetically-defined subset of approximately two forms of acute leukemia, acute myeloid leukemia (AML) and acute lymphoblastic.
Launch: KOMZIFTI launched in late 2025 and generated $2.1 million in net product revenue in the final weeks of the year; management describes the launch as "off to a strong start."
Access: Payers covering ~90% of insured lives were engaged pre-approval; ~84% of private payers established coverage within 90 days and some Blue plans have implemented step edits requiring KOMZIFTI before other menin inhibitors.
Differentiation: Management emphasizes KOMZIFTI's once-daily dosing, lack of azole dose adjustments, single boxed warning (differentiation syndrome) and combinability as competitive advantages.
Development: Registrational KOMET-017 frontline program is enrolling (~200 global sites) with first topline Phase III results anticipated in 2028; multiple combination readouts (including gilteritinib) and KOMET-007 updates expected in 2026.
Second platform: FTI program darlifarnib advancing in combinations (cabozantinib, adagrasib) with Phase Ib randomized expansion initiated in RCC and additional readouts planned in 2026.
Financials & runway: Q4 collaboration revenue was $15.2 million; R&D $64.4 million; SG&A $39.1 million; net loss $8 million. Cash, cash equivalents and short-term investments were $667.2 million at year-end 2025; collaboration revenue guidance provided for 2026–2028.
